Enfuvirtide is an HIV-1 gp41 fusion inhibitor used in patients experiencing HIV-1 replication who are already being treated with other anti-retrovirals. Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake.
- Mechanism
- Curator reviewed
Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. By disrupting the HIV-1 molecular machinery during its final stage of fusion with the target cell, enfuvirtide limits the spread of further infection. Enfuvirtide is a biomimetic peptide that was rationally designed to mimic components of the HIV-1 fusion machinery and displace them, preventing normal fusion.
- Primary indication
- Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.Curator reviewed · 1 structured indication
- Formula / weight
- C204H301N51O64 · 4491.876 Da
- First approval
- Canada, 2003 · United States, 2006 · European Union, 2016
- Code names
- DP-178 · T-20
- Brand names
Resolves to
What you can answer from here — as of September 12, 2026
Which drugs share a target with Enfuvirtide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account